KROS vs WY · rev $32.0K vs P/E 43, rev $3.59B
Keros Therapeutics Inc (KROS) versus Weyerhaeuser Company (WY) — a side-by-side from cached financials, not a winner call.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Weyerhaeuser Company (WY) is a reit - specialty company listed on NYSE.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
Latest reported WY revenue for 2026-06-30 was $3.59B. Net income was $318.0M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
KROS currently screens at market cap $208.8M. WY currently screens at market cap $17.54B and trailing P/E 43.4.
Not investment advice. Open the KROS and WY stock pages for the full models.
Not investment advice.